Secondary end points of patients with LV functional studies (n = 51) 5 years after cardiac bone-marrow mononuclear cell (BM-MNC) therapy.

<p>Secondary end points of patients with LV functional studies (n = 51) 5 years after cardiac bone-marrow mononuclear cell (BM-MNC) therapy.</p

Primary end point: occurrence of adverse events during the 5-year follow-up.

<p>In patients with multiple events during the 5-year FUP, the most serious major adverse event was entered as MACCE and the composite of all adverse events (one/patient) for each patient.</p

Schematic display of the segmental transmurality and NOGA electromechanical mapping-derived parameter.

<p>(A) Schematic display of the segmental transmurality using MathLab software, showing a decrease in infarct transmurality over 5 years in patients with acute myocardial infarction who were treated with combined delivery of cells. Summed data from 26 patients. (B) NOGA electromechanical mapping-derived parameter in patients with or without major adverse events during the 5-year follow-up. *<i>p</i><0.05.</p

Left and right ventricular function in subgroup of patients.

<p>underwent single photon emission computed tomography (SPECT) and cardiac magnetic resonance imaging (cMRI) 5 years after cardiac bone-marrow mononuclear cell (BM-MNC) therapy.</p

Segmental infarct transmurality determined by cardiac magnetic resonance imaging (n = 26).

<p>Segmental infarct transmurality determined by cardiac magnetic resonance imaging (n = 26).</p

Gated ⁹⁹m-Sestamibi myocardial scintigraphy of a patient with cardiac bone marrow mononuclear cell (BM-MNC) treatment.

<p>(A) and (B) Before combined cardiac delivery of autologous BM-MNC treatment; 3-dimensional calculation of LV volume (A) and polar map of infarct size (B). (C) and (D) At the 1-year follow-up, 3-dimensional calculation of LV volume (C) and polar map for infarct size (D). (E) and (F) At the 5-year follow-up, 3-dimensional calculation of LV volume (E) and polar map for infarct size (F).</p

Left ventricular function and infarct size of patients randomized to Early or Late cell-therapy during the 5-year follow-up.

<p><b>Patients were treated with combined delivery of autologous BM-MNC.</b> Global left ventricular (LV) ejection fraction, wall motion score index (measured by echocardiography), and infarct size (by single photon emission computed tomography) of patients in the Early and Late groups before receiving cardiac BMMNCs therapy and 1 and 5 years post cell therapy. No differences between the Early and Late group were observed.</p